Form 4 for DXCM Dexcom
Accepted 2026-02-02 00:00:00 ET · period of report 2026-01-29 · accession 0001093557-26-000012 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-02 | 2026-01-29 | DXCM | Stern Sadie | EVP, Chief HR Off | F - Tax | $73.36 | -2,656 | 109.7K | -2% | -$194.8K | |
| 2026-02-02 | 2026-01-29 | DXCM | Stern Sadie | EVP, Chief HR Off | A - Grant | $0.00 | +7,123 | 112.3K | +7% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-29 | F | D | 2,656 | $73.36 | 109,690 | D | — | — | (F2) Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of PSUs and does not represent a sale by the Reporting Person. (F3) Included in this number are 74,450 unvested restricted stock units, 29,922 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 14,474 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026. |
| 2 | Common | Common Stock | 2026-01-29 | A | A | 7,123 | $0.00 | 112,346 | D | — | — | (F1) Represents shares issued to the Reporting Person upon vesting of performance-based restricted stock units (PSUs) granted to the Reporting Person on March 8, 2023, resulting from achievement of performance conditions under the PSUs. |